This CME program will feature four HCV experts reviewing and discussing the most important studies presented on chronic hepatitis C at AASLD. This review and discussion will provide unique insight into how knowledgeable experts review the key posters and presentations at AASLD and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed.
This program will enable all participating clinicians and health care providers caring for HCV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care.
This activity has been designed to meet the educational needs of physicians involved in the management of patients with HCV infection.
After completing this activity, participants should be able to:
Review and discuss clinically relevant posters and presentations on chronic hepatitis C made at AASLD;
Explain to colleagues the clinical trials and data presented in the most important posters and presentations on chronic hepatitis C at AASLD;
Explain and discuss the scientific integrity and clinical relevance of the most important posters and presentations on chronic hepatitis C at AASLD;
Use the information and data presented in the most important posters and presentations at AASLD to improve patient care.
Release Date: November 9, 2010
Expiration Date: November 9, 2011
Estimated time to complete each Poster/Presentation: 15-30 minutes
Media: Internet
Douglas T. Dieterich, MD,
Professor of Medicine and Director of CME,
Department of Medicine,
Director of Outpatient Hepatology,
Division of Liver Diseases,
Mount Sinai School of Medicine
New York, New York
Paul Y. Kwo, MD
Associate Professor of Medicine
Medical Director, Liver Transplantation
Division of Gastroenterology and Hepatology
Indiana University School of Medicine
Indianapolis, Indiana
Paul J. Pockros, MD
Head, Division of Gastroenterology/Hepatology
Director, SC Liver Research Consortium
The Scripps Clinic
La Jolla, California
Jurgen Rockstroh, MD
Professor
University of Bonn
Bonn, Germany
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine (PIM) and ViralEd, Inc.. PIM is accredited by the ACCME to provide continuing medical education for physicians.
PIM designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM per poster presentation. Physicians should only claim credit commensurate with the extent of their participation in the activity
The Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Dr. Douglas Dieterich:
Dr. Paul Kwo:
Dr. Paul Pockros:
Dr. Jurgen Rockstroh:
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following planners and managers, Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kimball, RN, BSN; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine (PIM), ViralEd, Inc. and Merck & Co. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, ViralEd, Inc. and Merck & Co. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 |
HCV Treatment Duration in HIV/HCV G1 Co-infected Patients, EXTENT Trial and Increasing Frequency of HCC in HIV-infected Patients |
 |
ADVANCE Study: Final Results of Phase 3 |
 |
SPRINT-2: Final Results |
 |
ILLUMINATE Study: Final Results of Phase 3 |
 |
HCV RESPOND-2 Study: Final Results |
 |
Lambda in Combination with RBV, Treatment Naïve - Phase 2 |
 |
Non-response to Peginterferon Alfa and Ribavirin in IL28B CC & CT Patients can be Overcome by High Dose Continuous Interferon Alfa-2b Administration in Combination with Ribavirin for Chronic HCV |
 |
Dual, Triple, and Quadruple Combination Treatment with GS-9256 and GS-9190 Alone and with RBV in Treatment Naïve G1 HCV Subjects |
 |
Posters LB-7 and LB-8 |
 |
HCV Debrief 2010 |
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Supported by an educational grant from Merck & Co., Inc.
*This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings
